Cimlanod

Cimlanod
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name N-Hydroxy-5-methylfuran-2-sulfonamide;
CAS Number	1620330-72-4;
PubChemCID	76685198;
DrugBank	DB14983;
UNII	2US4FK1EPV;
CompTox Dashboard(EPA)	DTXSID801288087;
Chemical and physical data
Formula	C5H7NO4S
Molar mass	177.17g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=CC=C(O1)S(=O)(=O)NO;

Cimlanod(development codesCXL-1427andBMS-986231) is an experimental drug for the treatment ofacute decompensated heart failure.It was discovered by Cardioxyl Pharmaceuticals, which was acquired byBristol-Myers Squibb.It is aprecursorofnitroxyl.^[1]

Cimlanod is aprodrugof CXL-1020.^[2]

A preliminary study showed efficacy in patients with class III and IV heart failure.^[3]A phase II clinical trial was completed in 2016.^[4]

References

^"BMS 986231".AdisInsight.Springer Nature Switzerland AG.Retrieved2017-05-22.Alternative Names: BMS-986231; CXL 1427; HNO Donor
^"CXL 1020".AdisInsight.Springer Nature Switzerland AG.Retrieved2017-05-22.
^Zoler ML (22 May 2016)."Nitroxyl prodrug shows promise in acute heart failure".
^Clinical trial numberNCT02157506for "A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure" atClinicalTrials.gov

Thisdrugarticle relating to thecardiovascular systemis astub.You can help Wikipedia byexpanding it.